Alkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow ALKS
Alkermes plc (ALKS) P/E ratio
As of 16 October 2026, Alkermes plc (ALKS) trades at a P/E ratio of 102×. Over the past ten years it has ranged from 0.0× (June 2023) to 137× (July 2026); the current reading is higher than 98% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 19.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 19.0× | 47.59% |
| FY2024 | 12.9× | (3.12%) |
| FY2023 | 13.3× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 130× | 241.98% |
| Mar 2026 | 38.0× | 99.76% |
| Dec 2025 | 19.0× | 31.33% |
| Sep 2025 | 14.5× | 8.40% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | n/m |
| HIMS Hims & Hers Health, Inc. compare | n/m |
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| INDV Indivior Pharmaceuticals Inc. compare | 11.2× |
| LNTH Lantheus Holdings, Inc. compare | 23.7× |
| RDY Dr. Reddy's Laboratories Ltd compare | 32.9× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 38.4× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 73.4× |
| ALKS Alkermes plc | 102× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)